MAIA Biotechnology rises on lung cancer drug trial data

Maia Biotechnology

04/02/2025 19:07

** Shares of cancer drug developer MAIA Biotechnology
 MAIA.A  rise 16.4% to $2.20
    ** Co says its experimental drug, THIO, helped patients with
a type of lung cancer live for a median of 16.9 months, in
mid-stage trial
    ** THIO was generally well-tolerated in patients who had
received multiple previous treatments, co says
    ** Co says it is considering the possibility of accelerated
FDA approval of THIO
    ** THIO gained 66.4% in 2024

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))